Document Detail


Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
MedLine Citation:
PMID:  14962264     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Imatinib mesylate is a potent, selective inhibitor of the tyrosine kinase activity of bcr-abl,which is now established as the state-of-the-art treatment for chronic, accelerated or even blastic phase of Philadelphia-positive [Ph(1)(+)] chronic myelogenous leukemia. It is also active in Ph(1)(+) acute lymphoblastic leukemia, but its role in Ph(1)(+) acute myeloid leukemia (AML) is less well investigated. We report here a patient with chemoresistant Ph(1)(+) AML, who responded promptly to one cycle of Ida-FLAG second-line chemotherapy by achieving complete morphologic, immunophenotypic, and cytogenetic remission but not a molecular one. The addition of imatinib mesylate led to a molecular remission, which is sustained for 10 months so far.
Authors:
Nora-Athina Viniou; Theodoros P Vassilakopoulos; Xanthi Giakoumi; Marina Mantzouranis; Gerassimos A Pangalis
Related Documents :
10400374 - Tailoring the treatment of acute myeloid leukemia.
18720364 - Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndr...
22326484 - Effect of asthma exacerbations on health care costs among asthmatic patients with moder...
12469194 - Determination of the in vivo effects of prednisone on bcl-2 family protein expression i...
22445874 - Adult congenital heart disease: new challenges.
16798924 - Digital panoramic radiography: a reliable method to diagnose carotid artery atheromas?
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  European journal of haematology     Volume:  72     ISSN:  0902-4441     ISO Abbreviation:  Eur. J. Haematol.     Publication Date:  2004 Jan 
Date Detail:
Created Date:  2004-02-13     Completed Date:  2004-03-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8703985     Medline TA:  Eur J Haematol     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  58-60     Citation Subset:  IM    
Affiliation:
First Department of Internal Medicine, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece. jbnv@otenet.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Agents / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  therapeutic use*
Cytarabine / administration & dosage
Female
Filgrastim / administration & dosage
Humans
Idarubicin / administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Salvage Therapy
Treatment Outcome
Vidarabine / administration & dosage,  analogs & derivatives*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Ida-FLAG protocol; 0/Piperazines; 0/Pyrimidines; 121181-53-1/Filgrastim; 147-94-4/Cytarabine; 152459-95-5/imatinib; 5536-17-4/Vidarabine; 58957-92-9/Idarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thalidomide for the treatment of idiopathic myelofibrosis.
Next Document:  Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).